Search Results - "FABIAN, Carol"

Tamoxifen: Will Less Equal More in Women with Precancerous Breast Disease? by Fabian, Carol J

“…Similar risk reduction but fewer side effects would predict more uptake and compliance with low (5 mg) versus full (20 mg) dose tamoxifen. Benefit with low…”
Get full text

Will a Low-Dose Option Improve Uptake of Tamoxifen for Breast Cancer Risk Reduction? by Fabian, Carol J

Get full text

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline by Armenian, Saro H, Lacchetti, Christina, Barac, Ana, Carver, Joseph, Constine, Louis S, Denduluri, Neelima, Dent, Susan, Douglas, Pamela S, Durand, Jean-Bernard, Ewer, Michael, Fabian, Carol, Hudson, Melissa, Jessup, Mariell, Jones, Lee W, Ky, Bonnie, Mayer, Erica L, Moslehi, Javid, Oeffinger, Kevin, Ray, Katharine, Ruddy, Kathryn, Lenihan, Daniel

“…Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies that can interfere with the efficacy of treatment, decrease…”
Get full text

American Society of Clinical Oncology position statement on obesity and cancer by Ligibel, Jennifer A, Alfano, Catherine M, Courneya, Kerry S, Demark-Wahnefried, Wendy, Burger, Robert A, Chlebowski, Rowan T, Fabian, Carol J, Gucalp, Ayca, Hershman, Dawn L, Hudson, Melissa M, Jones, Lee W, Kakarala, Madhuri, Ness, Kirsten K, Merrill, Janette K, Wollins, Dana S, Hudis, Clifford A

“…Rates of obesity have increased significantly over the last three decades in the United States and globally. In addition to contributing to heart disease and…”
Get full text

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy by Moore, Halle C.F, Unger, Joseph M, Phillips, Kelly-Anne, Boyle, Frances, Hitre, Erika, Porter, David, Francis, Prudence A, Goldstein, Lori J, Gomez, Henry L, Vallejos, Carlos S, Partridge, Ann H, Dakhil, Shaker R, Garcia, Agustin A, Gralow, Julie, Lombard, Janine M, Forbes, John F, Martino, Silvana, Barlow, William E, Fabian, Carol J, Minasian, Lori, Meyskens, Frank L, Gelber, Richard D, Hortobagyi, Gabriel N, Albain, Kathy S

“…Women with hormone-receptor–negative breast cancer who received goserelin with adjuvant chemotherapy had less amenorrhea and better fertility at 2 years after…”
Get full text

Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update by Visvanathan, Kala, Fabian, Carol J, Bantug, Elissa, Brewster, Abenaa M, Davidson, Nancy E, DeCensi, Andrea, Floyd, Justin D, Garber, Judy E, Hofstatter, Erin W, Khan, Seema A, Katapodi, Maria C, Pruthi, Sandhya, Raab, Rachal, Runowicz, Carolyn D, Somerfield, Mark R

“…To update the ASCO guideline on pharmacologic interventions for breast cancer risk reduction and provide guidance on clinical issues that arise when deciding…”
Get full text

Reduced-Frequency Endocrine Therapy and Challenges of Noninferiority Study Designs by Fabian, Carol J, Mudaranthakam, Dinesh Pal

Get more information

Exemestane for Breast-Cancer Prevention in Postmenopausal Women by Goss, Paul E, Ingle, James N, Alés-Martínez, José E, Cheung, Angela M, Chlebowski, Rowan T, Wactawski-Wende, Jean, McTiernan, Anne, Robbins, John, Johnson, Karen C, Martin, Lisa W, Winquist, Eric, Sarto, Gloria E, Garber, Judy E, Fabian, Carol J, Pujol, Pascal, Maunsell, Elizabeth, Farmer, Patricia, Gelmon, Karen A, Tu, Dongsheng, Richardson, Harriet

“…In postmenopausal women at increased risk for breast cancer, exemestane reduced the annual incidence of invasive breast cancer by 65% after a median follow-up…”
Get full text

Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline by VISVANATHAN, Kala, HURLEY, Patricia, GARBER, Judy, KATAPODI, Maria, KRAMER, Barnett, MORROW, Monica, PARKER, Barbara, RUNOWICZ, Carolyn, VOGEL, Victor G, WADE, James L, LIPPMAN, Scott M, BANTUG, Elissa, BROWN, Powel, COL, Nananda F, CUZICK, Jack, DAVIDSON, Nancy E, DECENSI, Andrea, FABIAN, Carol, FORD, Leslie

“…To update the 2009 American Society of Clinical Oncology guideline on pharmacologic interventions for breast cancer (BC) risk reduction. A systematic review of…”
Get full text

A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer by Gajewski, Byron J, Kimler, Bruce F, Koestler, Devin C, Mudaranthakam, Dinesh Pal, Young, Kate, Fabian, Carol J

“…Our randomized controlled clinical trial will explore the potential of bazedoxifene plus conjugated estrogen to modulate breast tissue-based risk biomarkers as…”
Get full text

The flaxseed lignan secoisolariciresinol diglucoside decreases local inflammation, suppresses NFκB signaling, and inhibits mammary tumor growth by Bowers, Laura W., Lineberger, Claire G., Ford, Nikki A., Rossi, Emily L., Punjala, Arunima, Camp, Kristina K., Kimler, Bruce K., Fabian, Carol J., Hursting, Stephen D.

“…Purpose Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with…”
Get full text

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials by Skates, Steven J, Greene, Mark H, Buys, Saundra S, Mai, Phuong L, Brown, Powel, Piedmonte, Marion, Rodriguez, Gustavo, Schorge, John O, Sherman, Mark, Daly, Mary B, Rutherford, Thomas, Brewster, Wendy R, O'Malley, David M, Partridge, Edward, Boggess, John, Drescher, Charles W, Isaacs, Claudine, Berchuck, Andrew, Domchek, Susan, Davidson, Susan A, Edwards, Robert, Elg, Steven A, Wakeley, Katie, Phillips, Kelly-Anne, Armstrong, Deborah, Horowitz, Ira, Fabian, Carol J, Walker, Joan, Sluss, Patrick M, Welch, William, Minasian, Lori, Horick, Nora K, Kasten, Carol H, Nayfield, Susan, Alberts, David, Finkelstein, Dianne M, Lu, Karen H

“…Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each woman has her own CA125 baseline;…”
Get full text

Omega-3 fatty acids for breast cancer prevention and survivorship by Fabian, Carol J, Kimler, Bruce F, Hursting, Stephen D

“…Women with evidence of high intake ratios of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to the omega-6…”
Get full text

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230 by Moore, Halle C F, Unger, Joseph M, Phillips, Kelly-Anne, Boyle, Frances, Hitre, Erika, Moseley, Anna, Porter, David J, Francis, Prudence A, Goldstein, Lori J, Gomez, Henry L, Vallejos, Carlos S, Partridge, Ann H, Dakhil, Shaker R, Garcia, Agustin A, Gralow, Julie R, Lombard, Janine M, Forbes, John F, Martino, Silvana, Barlow, William E, Fabian, Carol J, Minasian, Lori M, Meyskens, Frank L, Gelber, Richard D, Hortobagyi, Gabriel N, Albain, Kathy S

“…Premature menopause is a serious long-term side effect of chemotherapy. We evaluated long-term pregnancy and disease-related outcomes for patients in…”
Get full text

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing by Sharma, Priyanka, Klemp, Jennifer R., Kimler, Bruce F., Mahnken, Jonathan D., Geier, Larry J., Khan, Qamar J., Elia, Manana, Connor, Carol S., McGinness, Marilee K., Mammen, Joshua M. W., Wagner, Jamie L., Ward, Claire, Ranallo, Lori, Knight, Catherine J., Stecklein, Shane R., Jensen, Roy A., Fabian, Carol J., Godwin, Andrew K.

“…NCCN guidelines recommend genetic testing for all triple-negative breast cancer (TNBC) patients aged ≤60 years. However, due to the lack of prospective…”
Get full text

Effects of Weight Loss and Weight Regain on Circulating Biomarkers in Overweight/Obese Breast Cancer Survivors Enrolled in a Weight Loss Trial in the Rural Midwest by Befort, Christie A, Kimler, Bruce F, Bantis, Leonidas E, Phillips, Teresa A, Fabian, Carol J

“…Obesity is associated with worse breast cancer prognosis, however little is known about the level of weight loss required to improve pathway biomarkers. The…”
Get full text

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane by VAHDAT, Linda T, PRUITT, Brian, SMITH, John, O'SHAUGHNESSY, Joyce, SHUSTER, Dale E, MENESES, Nicole L, CHANDRAWANSA, Kumari, FANG FANG, COLE, Patricia E, ASHWORTH, Simon, BLUM, Joanne L, FABIAN, Carol J, RIVERA, Ragene R, SMITH, David A, TAN-CHIU, Elizabeth, WRIGHT, Jonathan, TAN, Antoinette R, DACOSTA, NoshirA, CHUANG, Ellen

“…Eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analog of the marine natural product…”
Get full text

Adiponectin: a risk biomarker and attractive target for chemoprevention by Fabian, Carol J

Get full text

Translating energy balance research from the bench to the clinic to the community: Parallel animal‐human studies in cancer by Garcia, Miriam B., Schadler, Keri L., Chandra, Joya, Clinton, Steven K., Courneya, Kerry S., Cruz‐Monserrate, Zobeida, Daniel, Carrie R., Dannenberg, Andrew J., Demark‐Wahnefried, Wendy, Dewhirst, Mark W., Fabian, Carol J., Hursting, Stephen D., Irwin, Melinda L., Iyengar, Neil M., McQuade, Jennifer L., Schmitz, Kathryn H., Basen‐Engquist, Karen

“…Advances in energy balance and cancer research to date have largely occurred in siloed work in rodents or patients. However, substantial benefit can be derived…”
Get full text

Breast cancer and fertility preservation by Kim, S. Samuel, M.D, Klemp, Jennifer, Ph.D, Fabian, Carol, M.D

“…Objective To review the benefits of adjuvant systemic therapy given to women with breast cancer of reproductive age, its effects on fertility, and options for…”
Get full text